Has Inflammation a Significant Implication in Lung Cancer Evolution?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer

NCT07042867

Lung Cancer (Diagnosis)

NOT_YET_RECRUITING NA

Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients

NCT07242482

Lung Cancer (Diagnosis) Biomarkers / Blood

NOT_YET_RECRUITING

Role of Intrapulmonary Lymph Nodes in Patients With NSCLC and Visceral Pleural Invasion

NCT05596578

Lung Cancer Lymph Node Metastasis

RECRUITING

Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer

NCT02271581

Lung Neoplasms Carcinoma, Non-Small-Cell Lung

COMPLETED

Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer

NCT04918836

Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung neoplasms

Lung neoplasms irrespective of stage and histology

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lung neoplasms irrespective of stage, histology

Exclusion Criteria

* Previously treated lung neoplasms
* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No